02:10 , Oct 20, 2018 |  BioCentury  |  Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
19:57 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest endosome-targeting conjugates of CRLR and NK1R antagonists could help treat chronic pain. The conjugates were created by linking CRLR and NK1R antagonist tool compounds to the lipid cholestanol, which targets...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
19:39 , Jun 23, 2017 |  BC Week In Review  |  Company News

KeyBioscience grants Lilly rights to Type II diabetes platform

The KeyBioscience AG subsidiary of Nordic Bioscience A/S (Herlev, Denmark) granted Eli Lilly and Co. (NYSE:LLY) worldwide rights to develop and commercialize its Dual Amylin Calcitonin Receptor Agonist (DACRA) platform to develop compounds to treat...
08:00 , Nov 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis Sphingosine 1-phosphate receptor 3 (S1PR3; S1P3; EDG3); calcitonin receptor Mouse studies suggest antagonizing the calcitonin receptor or agonizing S1PR3 could help treat osteoporosis....
07:00 , May 23, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Adrenomedullin (ADM; AM) and calcitonin receptor-like (CRLR; CALCRL) levels to diagnose preeclampsia Mouse studies suggest monitoring levels of ADM or its receptor, CRLR, could enable early...
07:00 , May 23, 2013 |  BC Innovations  |  Tools & Techniques

Revisiting adrenomedullin in preeclampsia

A North Carolina team has shown that fetal deficiency in adrenomedullin resulted in mouse placental abnormalities similar to those found in preeclampsia, thereby underscoring adrenomedullin's potential as a marker for the indication. 1 Future studies...
08:00 , Jan 24, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Clostridium Calcitonin receptor-like (CALCRL; CRLR) Rat studies suggest decreasing CRLR expression in the intestines could help treat Clostridium difficile infection....
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

Oral salmon calcitonin: Phase II data

The double-blind, U.S. Phase II TAR01-201 trial in 129 postmenopausal women with low bone mass at an increased risk of fracture showed that once-daily 200 mg oral Ostora met the primary endpoint of superiority to...
08:00 , Dec 19, 2011 |  BC Week In Review  |  Clinical News

Oral salmon calcitonin: Development discontinued

Emisphere said partner Novartis discontinued development of SMC021 to treat postmenopausal osteoporosis and OA. Emisphere said the pharma's decision was based on data from the Phase III Study 2303 trial in postmenopausal osteoporosis and the...